| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Bortezomib | FIMM | pan-cancer | AAC | 0.41 | 0.02 |
| mRNA | avicin D | CTRPv2 | pan-cancer | AAC | 0.13 | 0.02 |
| mRNA | PI-103 | GDSC1000 | pan-cancer | AAC | 0.076 | 0.02 |
| mRNA | Methotrexate | CTRPv2 | pan-cancer | AAC | -0.092 | 0.02 |
| mRNA | PD173074 | GDSC1000 | pan-cancer | AAC | -0.087 | 0.02 |
| mRNA | temsirolimus | FIMM | pan-cancer | AAC | 0.44 | 0.02 |
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | -0.085 | 0.02 |
| mRNA | ML203 | CTRPv2 | pan-cancer | AAC | -0.094 | 0.02 |
| mRNA | BRD-A02303741:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.089 | 0.02 |
| mRNA | WZ4002 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.02 |